Dengue vaccine shows favorable safety profile in travelers from non-endemic regions

Article excerpt

A dengue vaccine called TAK-003 proved safe and well-tolerated in 1,028 travelers from dengue-free regions who received it in Catalonia, according to research published in The Lancet Regional Health Europe. The study, led by the Barcelona Institute for Global Health, found the vaccine had a favorable safety profile in routine clinical practice, a key finding for expanding vaccination among international travelers who lack prior dengue exposure. The research addresses a crucial gap: most dengue vaccines have been tested primarily in endemic populations with prior infection, making real-world data from non-endemic travelers particularly valuable for public health decisions.